Specific Azathioprine Dosing Schedule for a 70-kg Adult After Remission Induction
For a 70-kg adult who has achieved clinical remission after induction therapy, start azathioprine at 70 mg daily (1 mg/kg/day) on Day 1, then increase gradually to 105-140 mg daily (1.5-2 mg/kg/day) over 2-4 weeks as the steroid is tapered, with appropriate blood count monitoring.
Day-by-Day Dosing Protocol
Week 1 (Days 1-7): Initial Dosing
- Day 1-7: 50 mg daily (azathioprine)
- Continue prednisolone at current dose (typically being tapered from induction)
- Check TPMT activity before starting if not already done 1
Week 2 (Days 8-14): First Escalation
- Days 8-14: 75 mg daily (azathioprine)
- Continue prednisolone taper per induction protocol
Week 3 (Days 15-21): Second Escalation
- Days 15-21: 100 mg daily (azathioprine, ~1.4 mg/kg)
- Continue prednisolone taper (typically to 10-15 mg/day by this point)
Week 4+ (Day 22 onwards): Target Maintenance Dose
- Day 22+: 100-140 mg daily (azathioprine, 1.5-2 mg/kg/day)
- For a 70-kg patient, the target is typically 105-140 mg daily
- Continue tapering prednisolone to 5-10 mg/day over the next 1-3 months 1
Context-Specific Guidance
The dosing strategy differs based on the underlying condition:
For Autoimmune Hepatitis (Most Relevant Context)
The 2025 British Society of Gastroenterology guidelines provide the clearest framework 1:
- Standard starting dose: 1 mg/kg/day (70 mg for 70-kg patient)
- As steroids reduce: increase to 2 mg/kg/day (140 mg for 70-kg patient) 1
- The gradual escalation minimizes dose-dependent nausea 2
- Continue at 2 mg/kg/day indefinitely for maintenance after relapse 3
For ANCA-Associated Vasculitis
The 2024 KDIGO guidelines specify 4:
- Start at 1.5-2 mg/kg/day at complete remission (105-140 mg for 70-kg patient)
- Maintain for 18-24 months, then decrease to 1 mg/kg/day
- Continue until 4 years after diagnosis, then taper by 25 mg every 3 months
For Crohn's Disease
The 2025 AGA guidelines note 5:
- Typical dose: 2-2.5 mg/kg/day (140-175 mg for 70-kg patient)
- Used primarily for maintenance after steroid-induced remission
- Requires 16-24 weeks to assess full therapeutic effect
Critical Monitoring Requirements
Blood Count Monitoring Schedule 1
- Weeks 1-8: Weekly complete blood count (CBC)
- Months 3-12: Every 2-4 weeks
- After 12 months: Every 3 months
- Promptly reduce or stop if significant bone marrow depression occurs
Dose Adjustments for Special Populations
TPMT Heterozygous Deficiency 1, 6:
- Start at 50% of standard dose (35-50 mg daily for 70-kg patient)
- Increase more cautiously with closer monitoring
TPMT Homozygous Deficiency 1:
- Do not use azathioprine
- Consider mycophenolate mofetil instead
Age-Related Reductions 4:
- Age >60 years: 1.5 mg/kg/day (105 mg for 70-kg patient)
- Age >70 years: 1.0 mg/kg/day (70 mg for 70-kg patient)
Renal Impairment 4:
- GFR <30 ml/min/1.73 m²: Reduce by 0.5 mg/kg/day
Common Pitfalls to Avoid
Starting too high too fast: The gradual escalation from 50 mg minimizes nausea and vomiting, which are the most common reasons for discontinuation (14% in first year) 7
Inadequate monitoring: Leukopenia can develop at any time; the first follow-up CBC is particularly predictive of future toxicity 8
Premature discontinuation: Therapeutic effects take 6-8 weeks minimum, with optimal assessment at 12 weeks 5
Ignoring metabolite levels: If inadequate response despite good adherence, consider checking 6-thioguanine nucleotide levels (target 250-400 pmol/8×10⁸ RBC) 1, 9
Exceeding 2.5 mg/kg/day: Doses above this threshold show diminished efficacy and substantially increased adverse events 10